CHRISTINA NGUYEN: Open Payments
NPI 1457949943 · SAN JOSE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,085 in 27 payments from 11 companies in 2025. Trend: 2023 $1,434 · 2024 $1,960 · 2025 $1,085
Food & beverage: $985Education: $100
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 11 | $393 |
| Eisai Inc. | 3 | $178 |
| Astellas Pharma US Inc | 2 | $132 |
| AstraZeneca Pharmaceuticals LP | 1 | $121 |
| BLUEWIND MEDICAL | 3 | $82 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $43 |
| On Target Laboratories, Inc | 1 | $38 |
| Hologic Sales and Service, LLC | 1 | $35 |
| PFIZER INC. | 1 | $24 |
| ABBVIE INC. | 1 | $22 |
Products named: GEMTESA, Lenvima, LYNPARZA, REVI, JOURNAVX, Cytalux, ACESSA PROVU SYSTEM, Veozah.
Industry payments across CA — which companies pay providers there.
